The Roles of HBXAP Gene in Ovarian Cancer
The Roles of HBXAP Gene in Ovarian Cancer
批准号:
7582307
负责人:
IE-MING SHIH
金额:
$34.03万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2013-01-31
关键词:
AcuteAmino AcidsAnchorage-Independent GrowthAnimalsApoptosisApoptoticBindingBiological AssayBiological ProcessCancer cell lineCell Cycle ProgressionCell Cycle RegulationCell LineCell ProliferationCell-Free SystemCellsCessation of lifeChromatin Remodeling FactorClinicalClone CellsComplexDNA biosynthesisDataDependencyDevelopmentDominant-Negative MutationDrug resistanceEctopic ExpressionEpigenetic ProcessEpitheliumGenesGeneticGenetic TranscriptionGenotypeGrowthHumanIn VitroLifeMalignant NeoplasmsMalignant neoplasm of ovaryMapsMediatingMethylationModelingMolecularMolecular GeneticsMusMutateMutationNude MiceOncogene ActivationOncogenicOvarianOvarian CarcinomaOvarian Serous AdenocarcinomaOvaryPathogenesisPathway interactionsPhenotypeProteinsReporterRetroviridaeRoleSMARCA5 geneSignal TransductionSpecimenStressSubfamily lentivirinaeSurfaceSystemTP53 geneTestingTetanus Helper PeptideTimeTissuesTreatment ProtocolsTumor PromotionUp-RegulationWorkXenograft procedureabstractingangiogenesisbasecancer cellcancer therapycell growthcell typechromatin remodelingclinically significantdesigngenome-widein vivointraperitonealmouse modelmutantneoplastic celloverexpressionpre-clinicalpromoterresponsesmall hairpin RNAtherapeutic targettransduction efficiencytumortumor growthtumor progressiontumorigenesistumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The objective of this study is to characterize a recently identified tumor-associated gene, HBXAP (also known as Rsf-1), that is amplified in ovarian cancer. Over the past years, we have applied genome-wide analyses to delineate molecular genetic changes in ovarian cancer, and have identified a new amplified gene, HBXAP (Rsf-1), in ovarian carcinomas. Amplification and overexpression of HBXAP are significantly associated with the most aggressive type of ovarian cancer in clinical specimens. It has been known that HBXAP interacts with hSNF2H to form a chromatin remodeling complex. Indeed, we demonstrated that HBXAP co-immunoprecipitated with hSNF2H in ovarian caner cells, and expression of HBXAP promoted tumor cell growth and survival in p53 mutated cells but not in p53 wild-type cells. Based on the above findings, we hypothesize that p53 mutation facilitates cells to evade from the oncogene-induced growth suppression and apoptosis, and in the p53 mutant cells, increased HBXAP levels contributes to tumor progression by its binding to hSNF2H. Furthermore, HBXAP may serve as a potential therapeutic target in a preclinical mouse tumor model. To test the above hypotheses, we propose four closely integrated aims. Aim 1: Determine if formation of the HBXAP and hSNF2H chromatin remodeling complex is required for survival in ovarian cancer cells with HBXAP overexpression. Aim 2: Assess the roles of p53 mutations in HBXAP-induced tumor promotion. Aim 3: Assess if overexpression of HBXAP in combination with mutant p53 is essential for tumorigenesis and/or tumor progression. Aim 4: Determine the anti-tumor effects by targeting HBXAP in mouse ovarian cancer xenografts. Revealing the molecular context in deciphering the functions of a tumor-promoting gene is essential to understand the pathogenesis of cancer development and may have translational implications for new cancer therapy.
PUBLIC HEALTH RELEVANCE: Previous studies have shown that amplification and overexpression of HBXAP, a chromatin remodeling gene, are significantly associated with the most aggressive type of ovarian cancer. The objective of the current study is to characterize how HBXAP upregulation contributes to the development and progression of ovarian cancer. Revealing the molecular context in deciphering the functions of a tumor-promoting gene is essential to understand the pathogenesis of cancer development and may have translational implications for new cancer therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approach
-
批准号:10673186
-
项目类别:
-
资助金额:$92.31万
-
财政年份:2022
-
负责人:IE-MING SHIH
-
依托单位:
Role of cancer-associated mutations in endometriosis
-
批准号:10626987
-
项目类别:
-
资助金额:$66.09万
-
财政年份:2019
-
负责人:IE-MING SHIH
-
依托单位:
Role of cancer-associated mutations in endometriosis
-
批准号:9979935
-
项目类别:
-
资助金额:$69.82万
-
财政年份:2019
-
负责人:IE-MING SHIH
-
依托单位:
Role of cancer-associated mutations in endometriosis
-
批准号:10381500
-
项目类别:
-
资助金额:$66.96万
-
财政年份:2019
-
负责人:IE-MING SHIH
-
依托单位:
Admin Core
-
批准号:10478839
-
项目类别:
-
资助金额:$15.7万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"
-
批准号:10222607
-
项目类别:
-
资助金额:$25.61万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
SPORE in Ovarian Cancer
-
批准号:10478838
-
项目类别:
-
资助金额:$158.91万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"
-
批准号:10478850
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
SPORE in Ovarian Cancer
-
批准号:9975108
-
项目类别:
-
资助金额:$197.7万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
Admin Core
-
批准号:10222601
-
项目类别:
-
资助金额:$25.61万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
SPORE in Ovarian Cancer
-
批准号:10222600
-
项目类别:
-
资助金额:$230.48万
-
财政年份:2018
-
负责人:IE-MING SHIH
-
依托单位:
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer
-
批准号:10376915
-
项目类别:
-
资助金额:$30.91万
-
财政年份:2016
-
负责人:IE-MING SHIH
-
依托单位:
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer
-
批准号:9903253
-
项目类别:
-
资助金额:$53.46万
-
财政年份:2016
-
负责人:IE-MING SHIH
-
依托单位:
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer
-
批准号:8996905
-
项目类别:
-
资助金额:$46.32万
-
财政年份:2016
-
负责人:IE-MING SHIH
-
依托单位:
Tumor Suppressor Role of ARID1A
-
批准号:8400414
-
项目类别:
-
资助金额:$19.87万
-
财政年份:2011
-
负责人:IE-MING SHIH
-
依托单位:
Tumor Suppressor Role of ARID1A
-
批准号:8257679
-
项目类别:
-
资助金额:$17.62万
-
财政年份:2011
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:8009489
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:7471941
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:8209302
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
The Roles of HBXAP Gene in Ovarian Cancer
-
批准号:7760912
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2008
-
负责人:IE-MING SHIH
-
依托单位:
海外基金